Japan's Astellas Pharma has announced that it will acquire the Belgian biotech Ogeda for up to [euro]800 million, including milestone payments (Fig. 1). Ogeda's sole clinical asset, fezolinetant, is a small-molecule inhibitor of the neurokinin 3 receptor (NK3R), for which the company reported

中文翻译：

---

交易观察：Astellas收购使神经激肽3受体拮抗剂的复兴升温

日本的Astellas Pharma宣布将以高达8亿欧元的价格收购比利时生物技术公司Ogeda，包括里程碑付款（图1）。Ogeda唯一的临床资产fezolinetant是神经激肽3受体（NK3R）的一种小分子抑制剂，该公司报道了这一点。